Sarah B. Colella, RN, BSN
Massachusetts General Hospital Cancer Center, Boston, MAAuthored Items
November 9, 2018 | November 2018 Vol 9, NO 11
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in breast cancer and can promote tumor growth, progression, and resistance to anticancer therapies such as endocrine therapy (ET).
Last modified: December 19, 2018